The mechanism debate in psilocybin therapy for depression
EBioMedicine August 1, 2026 DOI: 10.1016/j.ebiom.2026.106440 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Depression Psilocybin |
| Key points | A phase 2b trial showed that one dose of synthetic psilocybin with psychological support approximately doubled depression-score reduction at three weeks versus a low-dose control, but the benefit was unclear by twelve weeks. Phase 3 results remain unreviewed company announcements. |
Abstract
The use of psilocybin for treatment-resistant depression (TRD) is moving towards clinical use, and two unresolved questions will shape what comes next: how large and durable the benefit is, and what produces it? The strongest peer-reviewed efficacy signal is a phase 2b trial, in which one dose of synthetic psilocybin with psychological support approximately doubled the depression-score reduction at 3 weeks versus a low-dose control, although the benefit was unclear by 12 weeks. Potentially pivotal phase 3 results remain topline company announcements; however, these have not yet been peer reviewed.